tiprankstipranks
Advertisement
Advertisement
Benitec Biopharma: Buy Rating Reiterated on Promising BB-301 Data and Solid Cash Runway; $32 Price Target Maintained
PremiumRatingsBenitec Biopharma: Buy Rating Reiterated on Promising BB-301 Data and Solid Cash Runway; $32 Price Target Maintained
2M ago
Benitec Biopharma Reaffirmed at Buy on Strong Cash Runway and Clear BB-301 Pivotal Path in OPMD Dysphagia
Premium
Ratings
Benitec Biopharma Reaffirmed at Buy on Strong Cash Runway and Clear BB-301 Pivotal Path in OPMD Dysphagia
3M ago
Benitec Biopharma initiated with an Outperform at Evercore ISI
Premium
The Fly
Benitec Biopharma initiated with an Outperform at Evercore ISI
3M ago
Benitec Biopharma files to sell 1.48M shares of common stock for holders
PremiumThe FlyBenitec Biopharma files to sell 1.48M shares of common stock for holders
6M ago
Benitec Biopharma first patient treated in Cohort 1 of BB-301 Phase 1b/2a study
Premium
The Fly
Benitec Biopharma first patient treated in Cohort 1 of BB-301 Phase 1b/2a study
7M ago
Benitec Biopharma Concludes 2025 Annual Stockholders Meeting
Premium
Company Announcements
Benitec Biopharma Concludes 2025 Annual Stockholders Meeting
8M ago
Benitec Biopharma reports Q1 EPS (22c), consensus (33c)
PremiumThe FlyBenitec Biopharma reports Q1 EPS (22c), consensus (33c)
9M ago
Benitec Biopharma Announces $100 Million Public Offering
Premium
Company Announcements
Benitec Biopharma Announces $100 Million Public Offering
9M ago
Benitec Biopharma $100M share Spot Secondary priced at $13.50
Premium
The Fly
Benitec Biopharma $100M share Spot Secondary priced at $13.50
9M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100